Functional Significance of Secreted Frizzled-Related Protein 1 in Metastatic Renal Cell Carcinomas

被引:42
作者
Saini, Sharanjot
Liu, Jan
Yamamura, Soichiro
Majid, Shahana
Kawakami, Kazumori
Hirata, Hiroshi
Dahiya, Rajvir [1 ]
机构
[1] Vet Affairs Med Ctr, Dept Urol, Urol Res Ctr 112F, San Francisco, CA 94121 USA
关键词
WNT ANTAGONIST SFRP1; BETA-CATENIN; HISTONE MODIFICATIONS; DNA METHYLATION; SUPPRESSOR GENE; FAMILY GENES; EXPRESSION; CANCER; TUMOR; LUNG;
D O I
10.1158/0008-5472.CAN-09-1254
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The secreted Frizzled-related protein 1 (SFRP1) is a Wingless-type (Writ) antagonist that has been associated with various malignancies, including renal cell carcinomas (RCC). However, the functional significance of SFRP1 has never been investigated in metastatic RCC. Here, we investigated the role of this molecule in kidney cancer progression and metastasis. Using Writ pathway-focused cDNA expression profiling in normal renal, primary RCC, and metastatic RCC cell lines, we identified that SFRP1 is up-regulated in metastatic RCC. SFRP1 overexpression in metastatic RCC was confirmed by immunostaining in renal tissues. We explored the molecular mechanisms underlying SFRP1 up-regulation by analyzing DNA methylation and historic modification patterns on SFRP1 promoter. We found that this gene is unmethylated/hypomethylated and enriched in activating histone modifications in metastatic RCC. To understand the functional significance of SFRP1 overexpression in metastatic RCC with regard to tumorigenesis, we used a small interfering RNA-mediated approach to knockdown the gene and monitored cellular proliferation, apoptosis, and metastatic behavior. Proliferation was unaltered and apoptosis increased on attenuation of SFRP1 expression. Also, SFRP1 depletion decreased the invasive potential of the metastatic RCC cell line, suggesting that the overexpression of this Writ antagonist may be related to invasiveness and metastatic behavior in RCC. We investigated the molecular basis of the role of SFRP1 in invasion and metastasis and found that matrix metalloproteinase MMP10 is regulated by SFRP1. in conclusion, our data suggest that SFRP1 plays a role in the metastatic potential of RCC. The present findings may be important in the design of treatment modalities for metastatic RCC. [Cancer Res 2009;69(17):6815-22]
引用
收藏
页码:6815 / 6822
页数:8
相关论文
共 49 条
  • [1] Methylation-associated silencing of SFRP1 in renal cell carcinoma
    Awakura, Yasuo
    Nakamura, Eijiro
    Ito, Noriyuki
    Kamoto, Toshiyuki
    Ogawa, Osamu
    [J]. ONCOLOGY REPORTS, 2008, 20 (05) : 1257 - 1263
  • [2] Mechanisms underlying epigenetically mediated gene silencing in cancer
    Baylin, SB
    [J]. SEMINARS IN CANCER BIOLOGY, 2002, 12 (05) : 331 - 337
  • [3] Functional interaction of beta-catenin with the transcription factor LEF-1
    Behrens, J
    vonKries, JP
    Kuhl, M
    Bruhn, L
    Wedlich, D
    Grosschedl, R
    Birchmeier, W
    [J]. NATURE, 1996, 382 (6592) : 638 - 642
  • [4] Bilim V, 2000, CLIN CANCER RES, V6, P460
  • [5] Bohm M, 1997, UROL RES, V25, P161
  • [6] The Wnt antagonist sFRP1 in colorectal tumorigenesis
    Caldwell, GM
    Jones, C
    Gensberg, K
    Jan, S
    Hardy, RG
    Byrd, P
    Chughtai, S
    Wallis, Y
    Matthews, GM
    Morton, DG
    [J]. CANCER RESEARCH, 2004, 64 (03) : 883 - 888
  • [7] MMP expression profiling in recurred stage IB lung cancer
    Cho, NH
    Hong, KP
    Hong, SH
    Kang, S
    Chung, KY
    Cho, SH
    [J]. ONCOGENE, 2004, 23 (03) : 845 - 851
  • [8] Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma
    Dahl, E.
    Wiesmann, F.
    Woenckhaus, M.
    Stoehr, R.
    Wild, P. J.
    Veeck, J.
    Knuechell, R.
    Klopocki, E.
    Sauter, G.
    Simon, R.
    Wieland, W. F.
    Walter, B.
    Denzinger, S.
    Hartmann, A.
    Hammerschmied, C. G.
    [J]. ONCOGENE, 2007, 26 (38) : 5680 - 5691
  • [9] Dennis S, 1999, J CELL SCI, V112, P3815
  • [10] New functions for the matrix metalloproteinases in cancer progression
    Egeblad, M
    Werb, Z
    [J]. NATURE REVIEWS CANCER, 2002, 2 (03) : 161 - 174